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Abstract
Purpose Picoplatin is a new generation platinum designed
to overcome platinum resistance. The goal of this study was
to assess picoplatin anti-tumor activity and measure various
cellular parameters in small-cell lung cancer (SCLC) cells
resistant to cell killing by cisplatin and carboplatin.
Methods We developed several platinum-resistant SCLC
cell lines to evaluate picoplatin activity and drug resistance
mechanisms in vitro. Drug cytotoxicity was measured by
MTS assay. Total cellular platinum accumulation was
measured by inductively coupled plasma mass spectrome-
try (ICP-MS). Whole genome gene expression proﬁling
was carried out by microarray analysis.
Results Picoplatin retained signiﬁcant cytotoxic activity
in platinum-resistant SCLC lines compared to cisplatin and
carboplatin. Cellular picoplatin accumulation in platinum-
resistant and parental cells was high relative to levels of
cellular platinum found in the same cell lines after cisplatin
or carboplatin treatment. Gene expression analyses revealed
substantial differences in gene expression and high-
lighted speciﬁc annotation clusters in carboplatin-resistant
cells. In addition, a similar gene expression pattern was
observed in picoplatin-treated carboplatin-resistant and
parental cells.
Conclusions Our study demonstrates that picoplatin can
overcome carboplatin and cisplatin resistance. The results
suggest decreased platinum accumulation as a potential
mechanism of platinum resistance in SCLC cells, provide
candidate markers (e.g. several genes in the Hox, gluta-
thione biosynthetic process, and MAGE families) that may
serve as signatures for platinum resistance, support distinct
effects of picoplatin on SCLC cells compared to other
platinums, and provide a rationale to develop picoplatin for
the treatment of recurrent SCLC following initial therapy
with cisplatin or carboplatin.
Keywords Picoplatin (AMD473, JM473, ZD0473) 
Cisplatin  Carboplatin  Small-cell lung cancer 
Drug resistance  Platinum analog
Introduction
Platinum-based chemotherapy has been the primary treat-
ment for cancer patients diagnosed with small-cell lung
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United States, 82% of SCLC patients were treated with
either carboplatin or cisplatin in combination with etopo-
side (IntrisiQ, 2008). Despite high initial response rates of
40–90% [1], the majority of patients develop treatment
resistance. Effective second-line treatment for recurrent
SCLC is a major unmet medical need. There is no stan-
dard chemotherapy for second-line platinum-refractory
(no response to initial therapy) or platinum-resistant SCLC
(early relapse after initial therapy).
Currently, the understanding of platinum resistance
mechanisms is largely based on studies of cisplatin.
Resistance is multi-factorial and can vary between cell
lines and types and this ﬁnding is consistent with variable
responses to platinum therapies between patients with
similar tumor types. Several mechanisms of resistance have
been hypothesized and are related directly or indirectly to
the platinum DNA binding. Potential mechanisms of
resistance include processes that alter the net intracellular
accumulation of platinum due to inﬂux and efﬂux trans-
porters, the inactivation of platinum drugs once inside the
cell by thiol-containing proteins such as glutathione or
metallothionine, the removal of platinum adducts from
DNA by nucleotide excision repair, the status of DNA
mismatch repair and bypass of DNA adducts by DNA
polymerase, and the mechanisms that control apoptosis
(for review, see [2]).
Gene expression analysis has been used recently to
identify individual genes and pathways whose transcrip-
tional regulation contributes to platinum resistance. To
enable physicians to provide the most appropriate care for
individual patients, biomarkers for patient stratiﬁcation for
treatment as well as real-time monitoring of response are
needed; gene expression signatures may provide this much-
needed tool. A small number of recent publications report
gene expression analysis of platinum resistance in ovarian
cancer, osteosarcoma, esophageal cancer, and Hodgkin’s
lymphoma. For ovarian cancer, potential gene signatures
for resistance or correlation have been identiﬁed by pro-
ﬁling tumor samples from platinum responder and non-
responder patients [3] and by proﬁling the response to
carboplatin in an ovarian cell line [4]. Despite the potential
clinical beneﬁt, to date, no studies have been reported
characterizing gene expression in SCLC cell lines (resistant
or responsive to platinum agents) or SCLC clinical
samples.
Picoplatin (AMD473, JM473, ZD0473) is a new gen-
eration platinum-based analog designed to overcome plat-
inum resistance [5]. In vitro preclinical studies conﬁrmed
the ability of picoplatin to retain activity in the presence of
elevated levels of glutathione and also demonstrated that
picoplatin can overcome mechanisms which decrease
accumulation of cisplatin [6, 7]. The suggestive in vitro
ﬁndings were substantiated by in vivo preclinical obser-
vations: picoplatin has a greater anti-tumor effect on cis-
platin-resistant ovarian tumors relative to other platinum
agents [8].
Limited preclinical data are available regarding the
activity of picoplatin in SCLC. The only publication doc-
uments picoplatin cytotoxicity against two SCLC lines,
H69 and SBC-3, and against cisplatin-resistant derivatives
of these two lines [7]. The following report describes the
development of novel SCLC cell lines resistant to cisplatin
and carboplatin followed by their characterization and the
pharmacologic evaluation of picoplatin compared to other
platinums in these tumor cells.
Materials and methods
Cell culture and reagents
Small-cell lung cancer lines, DMS53 and DMS114, were
obtained from American Type Culture Collection
(Manassas, VA). DMS53 and DMS114 are cultured in
Waymouth’s MB 752/1 medium supplemented with 10%
FBS. Injection grade cisplatin (1 mg/ml) and carboplatin
(10 mg/ml) were obtained from Sicor (Irvine, CA) and
oxaliplatin (5 mg/ml) was obtained from Sanoﬁ-Aventis
(Bridgewater, NJ). Picoplatin (0.5 mg/ml) was provided by
Poniard Pharmaceuticals (South San Francisco, CA).
Drug selection
Drug-resistant sub-cultures were generated by repeated
cycling in increasing selection drug concentration accord-
ing to the following schedule: cells were treated in sup-
plemented media with selection drug for 7 days. Cells were
then gently washed and allowed to recover for 21 days in
fresh supplemented media without drug. During this time,
cells were tested for drug resistance. Drug concentrations
used for selection were increased incrementally until cell
lines acquired resistance. For DMS114, selection was ini-
tiated at 2 lM cisplatin and increased to 5 lMi n1lM
increments, and at 4 lM carboplatin and increased to
11 lMi n1lM increments. Similarly in DMS53, cisplatin
selection was from 3 to 6 lM, carboplatin from 5 to
11 lM, and oxaliplatin from 1 to 5 lM. These cell lines
were then cycled at maintenance drug concentrations to
retain resistance. In some cases, cell lines acquired durable
resistance to the selection drug after 10–12 rounds of
selection and no longer required cycling to maintain
resistance. In cell lines where continued cycling is neces-
sary to maintain drug resistance, cells in the recovery
period (7–21 days after removal of selection drug) were
used for experiments.
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An MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was
used to assess cytotoxicity. The CellTiter 96 AQueous Cell
Proliferation Assay (Promega, Madison, WI) was per-
formed essentially according to the manufacturer’s proto-
col. Brieﬂy, 10
4 cells per well were seeded in ﬂat bottom
96-well plates in supplemented media and allowed to
adhere overnight. Following the addition of a serial dilution
of drug, cells were incubated for 4 days. 20 ll of MTS
reagent was added to each well, and plates were incubated
for an additional 1–2 h at 37C before spectrometric
measurement of absorbance at 490 nm. Media-only back-
ground was subtracted from all samples. Data were ana-
lyzed using GraphPad Prism 5. Fifty percent inhibitory
concentration (IC50) values were calculated based on nor-
malized log transformed data using a non-linear regression
algorithm. The resistance factor (RF) serves as a measure
of drug resistance in resistant cells and is deﬁned as the
IC50 drug concentration of the resistant line divided by that
of the parental line.
Cellular platinum accumulation
Total cellular platinum accumulation was determined by
ICP-MS essentially as described by Kitada et al. [9].
Brieﬂy, 10
6 cells were seeded in supplemented media in
6-well plates and allowed to adhere overnight, washed with
PBS, and treated with drug in serum-free media for 24 h.
Cells were then washed three times with PBS, lysed and
sonicated in 1 ml H2O. A volume of 0.5 ml of sample was
then reacted with aqua regia, digested at 95C, and diluted
to a ﬁnal volume of 5 ml with H2O. Samples were analyzed
by conventional ICP-MS and quantiﬁed against a certiﬁed
standard using multi-point weighted linear regression
(CanTest, Burnaby, Canada).
Gene expression proﬁling by microarray
In supplemented Waymouth’s medium, 10
6 carboplatin-
resistant (7–21 days into the drug cycling recovery period)
and parental DMS53 cells were allowed to adhere over-
night and treated with drug for 24 h. RNA was extracted
using the RNeasy total RNA puriﬁcation kit (Qiagen,
Valencia, CA) according to manufacturer protocol. Total
RNA quality was determined using a Pico Chip on an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). Four independent batches of RNA were pre-
pared for gene expression proﬁling to allow for adequate
statistical power. Sample preparation, labeling, and array
hybridizations were performed according to standard pro-
tocols by the UCSF Shared Microarray Core Facilities and
Agilent Technologies (http://www.arrays.ucsf.edu and
http://www.agilent.com). Equal amounts of Cy3-labeled
cRNA target were hybridized to Agilent human whole
genome 4 9 44 K Ink-jet arrays (Agilent). Arrays were
scanned using the Agilent microarray scanner (Agilent)
and raw signal intensities were extracted with Feature
Extraction 10.1.1 software (Agilent). Coefﬁcients were
included to adjust for batch speciﬁc differences. Sub-
sequent gene ontology and functional clustering analyses
were performed using The Database for Annotation,
Visualization and Integrated Discovery (DAVID 2008;
NationalInstituteofAllergyandInfectiousDisease(NIAID),
NIH; [10, 11]).
Results
Generation of drug-resistant SCLC cell lines
As a part of our effort to characterize the mechanism of
action of the new generation platinum analog picoplatin in
SCLC cell lines, we also characterized the activities of
cisplatin and carboplatin, which are platinum-based drugs
used in the ﬁrst-line treatment of SCLC. Sensitivity to
cisplatin, carboplatin and picoplatin in DMS53 and
DMS114 was determined by measuring the inhibition of
proliferation at various test concentrations using an MTS-
based cytotoxicity assay. IC50 values were obtained by
non-linear regression of normalized transformed data.
Although oxaliplatin is not currently used in the treatment
of SCLC, it is we included oxaliplatin to compare picopl-
atin effectiveness to the current marketed platinum agents.
Relative cell cytotoxicity proﬁles were generated for
picoplatin, cisplatin, carboplatin, and oxaliplatin. Picoplatin
IC50 values were slightly higher than those of cisplatin and
oxaliplatin but substantially lower than that of carboplatin
(Fig. 1a). This ranking in these SCLC cell lines is consistent
with previous observations in ovarian cell lines [6].
We generated cisplatin-, carboplatin-, and oxaliplatin-
resistant SCLC lines in order to study the mechanisms of
acquired drug resistance. Drug-resistant lines were gener-
ated by repeat cycling of cells in increasing concentrations
of selection drug over time (see ‘‘Materials and Methods’’).
Simultaneously, we also attempted to generate picoplatin-
resistant SCLC lines with little success (unpublished
observations). Kelland et al. had similar ﬁndings in their
attempts to generate picoplatin-resistant ovarian cell lines
(personal communication). Resistance to oxaliplatin in
DMS53 cells was obtained more quickly (after 4 rounds)
and was more stable (no longer required cycling in drug to
retain resistance) than cisplatin or carboplatin, which is
consistent with a study by Stordal et al. [12] with H69 cells.
Cisplatin and carboplatin-resistant DMS53 and DMS114
Cancer Chemother Pharmacol (2011) 67:1389–1400 1391
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10–12 rounds of selection.
To assess whether picoplatin retains activity in plati-
num-resistant cells, we performed cytotoxicity assays
comparing IC50 drug concentrations in parental and resis-
tant cells (Fig. 1a). The resistance factor (RF) values with
the selection drug were 2–10, indicating that the cell lines
that had undergone successive rounds of drug selection
were resistant to the selection drug (Fig. 1b). The RF
values with picoplatin treatment in cisplatin, carboplatin, or
oxaliplatin-resistant cells remained at or near 1, with
exception of carboplatin-resistant DMS114 cells, which
showed some resistance to picoplatin. However, the same
cells showed markedly higher resistance to carboplatin.
These data demonstrate that picoplatin has the capacity to
overcome at least some mechanisms of resistance to cis-
platin and carboplatin (and oxaliplatin) in SCLC cells.
Cellular platinum accumulation after picoplatin
treatment
Multiple drug inﬂux and efﬂux mechanisms are known to
regulate intracellular drug levels and in turn play a role in
determining drug sensitivity [13]. Cellular drug accumu-
lation is a major topic of study in resistance to platinum
drugs. In order to ascertain whether cellular platinum
accumulation varies between picoplatin and other plati-
num drugs, lysates from cells treated with drug were
analyzed by ICP-MS for platinum. In all cases, platinum
accumulation was essentially linear through the drug
titration range for all drugs tested (Fig. 2a). In parental
DMS53 cells, carboplatin treatment resulted in the lowest
level of cellular platinum accumulation whereas picoplatin
treatment resulted in the highest level. Platinum accumu-
lation was not signiﬁcantly different in parental DMS53
after treatment with cisplatin or picoplatin (P[0.05).
However, cisplatin-resistant DMS53 accumulated signiﬁ-
cantly less platinum after cisplatin treatment compared to
picoplatin treatment (P\0.0003). In both parental and
carboplatin-resistant DMS53, picoplatin treatment resulted
in strikingly higher cellular platinum levels than carbo-
platin treatment (P\0.00005). Similar results were
observed in DMS114 cells (Supplementary Fig. S1).
Because platinum accumulation was linear over the treat-
ment concentrations used, it was possible to express the
data as an accumulation ratio, which is deﬁned as the
platinum accumulation in resistant cells divided by that of
parental cells for each drug concentration. We found that
this ratio was essentially constant over the concentration
ranges tested, which is expected given the linear relation-
ship between platinum accumulation and drug concentra-
tion (Fig. 2b). A number less than 1 indicates reduced drug
accumulation in resistant cells relative to parental cells.
Therefore, it was possible to calculate an average accu-
mulation ratio (Fig. 2c), which represents the fraction of
platinum accumulation in drug-resistant cells relative to its
Fig. 1 IC50 and RF values for
DMS53 and DMS114 parental
and resistant cell lines. a 50%
inhibitory concentration (IC50)
values (lM) measured in by the
MTS assay (18 point serial
titration) after treatment of drug
for 96 h. b Resistance factors
(RFs) for resistant cells were
calculated by dividing the IC50
value of the resistant line by that
of the corresponding parental
line within a single experiment.
Data are the average for at least
6 independent experiments. The
standard deviation is reported
for each IC50 and RF value.
Student’s t-test (two-tailed) was
used to determine p values.
p\0.05 is considered
signiﬁcant
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resistant DMS53 cells accumulated a lower level of their
respective selection drug when compared with parental cells
(62 and 52%, respectively; Fig. 2b), suggesting that inﬂux/
efﬂux mechanisms may be involved in drug resistance in
these cells. Cisplatin-resistant DMS114 cells accumulated
71% of the selection drug relative to parental cells, whereas
carboplatin-resistant DMS114 cells did not accumulate less
selection drug (91%, Supplementary Fig. S1). Strikingly,
platinum accumulation in cisplatin- and carboplatin-resistant
DMS53 cells treated with picoplatin remained unchanged
when compared with parental cells (104 and 99%, respec-
tively, Fig. 2a–c). Together, these data suggest that the
mechanisms involved in reducing platinum accumulation in
cisplatin- and carboplatin-resistant SCLC cells do not affect
platinum accumulation after picoplatin treatment.
Fig. 2 Total cellular platinum accumulation in parental and drug-
resistant DMS53 cells. a Cellular platinum levels versus drug
concentration. Attached cells were treated with drug (3, 10, and
30 lM) for 24 h, and lysates were harvested and analyzed by ICP-
MS. Platinum levels were normalized to protein concentration for
each sample. b Accumulation ratio is calculated by dividing the
amount of platinum per mg of protein for the resistant cells by that of
the parental cells. A ratio of one indicates that there is no difference in
platinum accumulation between resistant and parental cells whereas a
value of less than one represents reduced platinum accumulation in
resistant cells. c Average accumulation ratio was obtained by
averaging the ratios of the 3 concentrations tested for each drug.
This was possible because the accumulation did not change over the
drug concentration range used. Filled symbols = selection drug;
Open symbols = picoplatin. CisR = cisplatin-resistant line; Car-
boR = carboplatin-resistant line. Data are the average of 3 indepen-
dent experiments. Error bars represent the standard deviation for each
data point. *p\0.000025, Student’s t-test, two-tailed
Cancer Chemother Pharmacol (2011) 67:1389–1400 1393
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Drug resistance pathways such as drug transport, neutral-
ization, metabolism, decreased apoptosis, and improved
DNA repair have been suggested to be involved with drug
resistance in various cancer cell types. However, there has
been little done to discern the pathways of platinum
resistance in SCLC. Therefore, we sought to identify genes
and pathways that are differentially expressed between
carboplatin-resistant and parental SCLC cells. In addition,
gene expression changes after picoplatin or carboplatin
treatment were assessed.
Unsupervised hierarchical cluster analysis
In order to evaluate the gene expression changes between
treatments, an unsupervised hierarchical clustering analysis
was performed (Fig. 3). Because of the substantial basal
differences between carboplatin-resistant and parent cells,
treatment-induced fold changes were calculated relative to
the no treatment expression levels from their respective cell
lines. As expected, treatment replicates generally clustered
well (Fig. 3, x-axis dendrogram). Interestingly, clustering
of treatment-induced differential expression also resulted
in clustering of picoplatin-treated parental and carboplatin-
resistant samples, suggesting that picoplatin elicits a sim-
ilar response in both parental and carboplatin-resistant cells
but is distinct from that of carboplatin. Carboplatin-treated
parental samples clustered together whereas carboplatin-
treated carboplatin-resistant replicates clustered loosely
with no treatment replicates of both lines, suggesting that
gene expression was not substantially affected by selection
drug treatment in carboplatin-resistant cells. This is likely
explained by the relative lack of differential gene expres-
sion after carboplatin treatment of carboplatin-resistant
cells.
Analysis of individual genes most highly upregulated in
carboplatin-resistant DMS53 cells revealed a number of
Fig. 3 Dendrogram of two-dimensional hierarchical clustering anal-
ysis of differential expression by treatment. The heatmap indicates
log2 fold change of all sample replicates relative to the average across
arrays (aveA) for genes that were differentially expressed in any of
the treatment contrasts; red upregulated and green downregulated.
Due to the large basal gene expression differences between carbo-
platin-resistant and parental cells, fold changes were calculated
relative to the no treatment group of the respective cell line to discern
treatment-induced changes in each line. The line height of dendro-
grams indicates the Euclidean average distance between clusters.
Treatment groups are represented by color below the treatment
dendrogram on the x-axis (black parental, no treat; red parental,
carbo; green parental, pico; dark blue carboR, no treat; light blue
carboR, carbo; pink carboR, pico)
c
1394 Cancer Chemother Pharmacol (2011) 67:1389–1400
123genes linked to cancer (Table 1, Adj P\0.01, fold change
[5). For instance, phosphorylated HCLS1, known for its
function in immune synapse formation and chemotaxis,
is associated with poor prognosis in chronic lympho-
cytic leukemia [34]. Angiogenin is well known for its
pro-angiogenic properties [35] and may be involved in cell
proliferation and angiogenesis in lung adenocarcinoma
[36]. HOXB9 overexpression was frequently seen in lung
cancer [26], and its upregulation was found in Hodgkin
lymphoma and shown to be involved in proliferation and
Table 1 Highest differentially upregulated genes: no treatment, carboplatin-resistant (CarboR) versus parental
Gene name Description GenBank accession Expression ratio
(CarboR/Parental)
Adjusted
P Value
HCLS1 Hematopoietic cell-speciﬁc Lyn substrate 1 NM_005335 62.4 1.72E-16
UNQ2541 MSFL2541 NM_203347 33.5 5.23E-13
KLHL1 Kelch-like 1 (Drosophila) NM_020866 21.6 2.06E-10
SEPT1 Septin 1 NM_052838 18.4 6.34E-12
FUT3 Fucosyltransferase 3 (galactoside
3(4)-L-fucosyltransferase, Lewis blood group)
NM_000149 13.3 1.10E-10
TPM4 Tropomyosin 4 NM_003290 12.8 1.26E-13
ANG Angiogenin, ribonuclease, RNase A family, 5 NM_001145 12.3 9.98E-08
RNASE4 Ribonuclease, RNase A family, 4 NM_194430 11.2 9.89E-08
CLCA1 Chloride channel, calcium activated, family member 1 NM_001285 9.8 4.06E-06
LOC199725 Hypothetical protein LOC199725 XM_086001 9.4 2.11E-05
PNMA3 Paraneoplastic antigen MA3 NM_013364 9.1 1.34E-11
VCX3A Variable charge, X-linked 3A NM_016379 9.0 1.64E-06
PNMA5 Paraneoplastic antigen like 5 NM_052926 8.7 5.35E-13
LOC340061 Hypothetical protein LOC340061 NM_198282 8.6 3.86E-07
SUCNR1 Succinate receptor 1 NM_033050 8.5 8.00E-08
VCX Variable charge, X-linked NM_013452 8.3 1.84E-05
VCX2 Variable charge, X-linked 2 NM_016378 8.2 1.29E-06
PNMA6A Paraneoplastic antigen like 6A NM_032882 8.1 1.57E-06
FBXL13 F-box and leucine-rich repeat protein 13 NM_145032 8.1 1.20E-08
VCY Variable charge, Y-linked NM_004679 8.0 5.85E-09
VCX2 Variable charge, X-linked 2 NM_016378 8.0 5.98E-08
TMEM71 Transmembrane protein 71 NM_144649 7.8 4.59E-09
STMN2 Stathmin-like 2 NM_007029 7.4 1.00E-06
HOXB9 Homeobox B9 NM_024017 7.3 2.09E-12
ZNF179 Zinc ﬁnger protein 179 NM_007148 7.0 1.02E-10
TSPAN1 Tetraspanin 1 NM_005727 6.7 2.68E-09
FER1L3 Fer-1-like 3, myoferlin (C. elegans) NM_013451 6.6 1.13E-07
SEZ6 Seizure related 6 homolog (mouse) NM_178860 6.2 0.000643
COL8A1 Collagen, type VIII, alpha 1 NM_001850 6.0 1.74E-05
FER1L3 Fer-1-like 3, myoferlin (C. elegans) NM_013451 5.9 4.15E-08
ANXA3 Annexin A3 NM_005139 5.9 3.19E-08
LECT1 Leukocyte cell derived chemotaxin 1 NM_007015 5.8 0.000185
SHC2 SHC (Src homology 2 domain containing)
transforming protein 2 (SHC2)
XM_939572
(NM_012435)
5.8 0.001418
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta NM_001175 5.7 0.002958
PRSS16 Protease, serine, 16 (thymus) NM_005865 5.7 1.33E-06
BRDG1 BCR downstream signaling 1 NM_012108 5.5 0.001209
HOXC9 Homeobox C9 NM_006897 5.3 6.11E-12
FST Follistatin NM_013409 5.1 0.002365
HGD Homogentisate 1,2-dioxygenase (homogentisate oxidase) NM_000187 5.0 2.08E-05
Adjusted p value\0.01, greater than ﬁvefold differential expression
Cancer Chemother Pharmacol (2011) 67:1389–1400 1395
123apoptosis [37]. STMN2 was found to be upregulated in
hepatoma via beta-catenin/TCF, a key component of the
Wnt signaling pathway [38]. Interestingly, ﬁve genes in the
variable charge, X/Y-linked (VCX/Y) family and four
genes in the paraneoplastic antigen like (PNMA) family—
whose functions are not known—were upregulated more
than ﬁvefold in carboplatin-resistant cells.
Carboplatin-resistant versus parental, no treatment
A comparison of carboplatin-resistant and parental DMS53
cells revealed signiﬁcant baseline differences in gene
expression. Functional annotation cluster analyses
(DAVID) highlighted overrepresentation of genes in
homeodomain, glutathione biosynthetic/metabolic process,
MAGE, homophilic cell adhesion, and regulation of
phosphorylation functional groups in carboplatin-resistant
cells (Table 2, Adjusted P\0.05, fold change [2).
Underrepresented functional groups in carboplatin-resis-
tant cells include genes in blood coagulation/homeostasis/
wound healing, neuron development and differentiation,
EGF/EGF-like, and protease inhibitor functional groups.
Picoplatin versus no treatment, parental,
and carboplatin-resistant cells
In addition, we assessed differential gene expression after
picoplatin treatment versus no treatment in either parental
or carboplatin-resistant cells. Treatment with picoplatin
resulted in relatively few upregulated genes in both cell
lines, and consequently no striking functional clustering
patterns were found in either cell line (data not shown).
Downregulated functional gene clusters in parental cells
after picoplatin treatment include genes involved in M
phase of cell cycle and cyclins, phosphodiesterase, phorbol
ester binding, EGF/EGF like, and ion transport. Similarly,
picoplatin treatment in carboplatin-resistant cells led to
decreased expression of EGF/EGF-like and cell cycle
groups (data not shown). Notable among cell cycle genes
downregulated in both cell lines after picoplatin treatment
are cyclin A1, Polo-like kinase 1, and RAD51-like 1.
Picoplatin versus carboplatin treatment in parental cells
We also compared gene expression changes after picopl-
atin versus carboplatin treatment. The most striking
observation from functional clustering analyses was that
picoplatin treatment of parental cells reduced expression of
genes in ion transporter activity (ion/transmembrane, metal
cation, potassium ion, alkali metal ion) compared to car-
boplatin treatment. The majority of genes downregulated
by picoplatin in these clusters are related to neuronal cell
type or processes.
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Picoplatin is an investigational agent that has been evalu-
ated in[1100 cancer patients to date. Picoplatin has been
and continues to be evaluated as an anti-tumor agent as a
single agent or in combination with other cytotoxics in a
wide variety of tumor types. Two independent Phase II
monotherapy studies of picoplatin in SCLC demonstrated a
median overall survival of at least 27 weeks and were
comparable to other therapeutic options [43, 44]. In the
SPEAR (Study of Picoplatin Efﬁcacy After Relapse) piv-
otal Phase III trial conducted by Poniard Pharmaceuticals,
the efﬁcacy and safety of picoplatin in combination with
best supportive care (BSC) vs BSC alone was evaluated in
a total of 401 SCLC patients who were refractory to or who
progressed within 6 months of ﬁrst-line platinum-based
therapy. Picoplatin was well-tolerated with manageable
hematologic toxicity. Although the analysis of overall
survival (321 events) did not achieve statistical signiﬁcance
(P = 0.0895) in the intent-to-treat population, a statisti-
cally signiﬁcant imbalanced use of post-study chemother-
apy in favor of the BSC arm may have impacted this result
(P = 0.012). In 273 patients who did not receive post-
study chemotherapy, there is statistically signiﬁcant dif-
ference in overall survival in favor of the picoplatin arm
(P = 0.0345). More importantly, picoplatin demonstrated
signiﬁcant survival improvement in 294 refractory patients
who never responded or relapsed within 45 days
(P = 0.0173). Picoplatin addresses a major unmet need in
the treatment of second-line small-cell lung cancer as there
is currently no FDA approved therapy for patients who are
refractory or relapse within 45 days of ﬁrst-line platinum-
based therapy [22].
In this study, we demonstrated the ability of picoplatin
to overcome platinum drug resistance in SCLC using
newly generated cisplatin- and carboplatin-resistant SCLC
cell lines. These observations were consistent with a study
by Kawamura et al. [7], which showed continued sensi-
tivity to picoplatin in two cisplatin-resistant SCLC and two
cisplatin-resistant NSCLC lines. A number of resistance
mechanisms to platinum drugs have been postulated [2].
However, no reports of studies related to platinum resis-
tance have been done in small-cell lung cancer. In this
study, we identiﬁed decreased cellular platinum accumu-
lation after drug treatment as a potential mechanism that
could contribute to cisplatin and carboplatin resistance
in these cell lines. In both platinum-resistant cell lines,
picoplatin treatment resulted in high levels of cellular
platinum that were indistinguishable from those of parental
cells. Similar results were observed in human ovarian
cancer lines [6]. In addition, picoplatin appears to retain
cytotoxic activity against both these platinum-resistant
lines.
Gene expression microarray analysis has been useful to
identify signatures of drug resistance and provide potential
clinical biomarkers. A comprehensive study of the carbo-
platin-resistant cell line using gene expression proﬁling
revealed additional pathways that may potentially con-
tribute to carboplatin resistance. Functional annotation
clustering showed signiﬁcant upregulation of HOX-con-
taining genes, genes involved in glutathione biosynthesis,
and MAGE genes, many of which have been implicated in
cancer.
Our study shows that homeodomain (HOX)-containing
gene functional clusters are highly overrepresented in
carboplatin-resistant DMS53 cells (Table 2, Cluster 1).
HOX genes are well known for their role in development
and hematopoiesis [14, 15]. Their involvement in cancer
was initially identiﬁed in hematologic malignancies such as
myeloid lymphocytic leukemia where chromosomal trans-
location of HOX with Nup98 is thought to contribute to
tumorigenesis [16]. More recently, a signiﬁcant number of
studies suggest that the expression of HOX genes is dys-
regulated in multiple solid tumor types including SCLC
[17–19] and is involved in progression, invasion, metas-
tasis, and DNA repair [20–22]. For instance, the disruption
of HOX interaction with PBX leads to increased apoptosis
in NSCLC, RCC, and melanoma cells [23–25]. HOXA9
and HOXB9, both upregulated in carboplatin-resistant
DMS53 cells, were found to be frequently overexpressed in
lung cancer [26]. Interestingly, HOXB7, also upregulated
in carboplatin-resistant DMS53, is believed to be involved
in DNA repair [22]. Activation of HOX gene clusters has
been linked to poor survival and drug resistance in glio-
blastoma and resembles a self-renewal signature in leuke-
mia [27]. Little else is known regarding the role of HOX
genes in drug resistance.
Increased glutathione levels and glutathione-S-transfer-
ase activity have frequently been implicated in platinum
neutralization and resistance, and the correlation between
increased glutathione levels and drug resistance has been
well documented in multiple tumor types [28–33]. How-
ever, a causal relationship between the two has thus far not
been convincingly demonstrated to date. We found that
glutathione biosynthetic and metabolic processes were
overrepresented in carboplatin-resistant DMS53 relative to
parental DMS53 cells. Consistent with these data, total
cellular glutathione level was shown to be signiﬁcantly
higher in carboplatin-resistant DMS53 cells in a separate
set of experiments (Supplementary Fig. S2). Together,
these data show that upregulation of the glutathione path-
way is associated with carboplatin resistance and that
drug neutralization by glutathione may contribute to drug
resistance in SCLC. Although the results of our study do
not establish a causal relationship between increased glu-
tathione and drug resistance, they do suggest that the
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development of drug resistance in SCLC. Interestingly,
picoplatin retained cytotoxic activity against carboplatin-
resistant DMS53 cells, and cellular accumulation remained
high in both drug-resistant and parental cells, which sug-
gests that picoplatin is able to circumvent glutathione
mediated inactivation.
Expression of MAGE genes has been linked to SCLC
and suggested as possible biomarkers for detection as well
as potential targets for immune-based therapeutic modali-
ties [42, 43]. The ﬁrst melanoma-associated antigen
(MAGE-A1) was isolated from a melanoma cell line and
found to be recognized by cytotoxic T lymphocytes [44].
In subsequent years, numerous additional MAGE genes
were identiﬁed. MAGE genes are subclassiﬁed into four
groups (A-D) based on sequence homology and divided
into two subgroups (I, containing groups A-C, and II,
containing group D) based on expression pattern. Subgroup
I, also called cancer/testis antigens, are expressed in testis
and frequently in tumor cells and have become the subject
of substantial interest in tumor immunotherapy. Although
the functions of MAGE proteins have remained largely
elusive, they are believed to be involved in embryonic
development and aspects of tumor transformation and
progression. Our data suggest that upregulation of several
MAGE genes (MAGE A8, A9, A11, and B2) may be
related to the acquisition of resistance to carboplatin in
SCLC cells. If conﬁrmed, these observations could poten-
tially have utility in predicting SCLC resistance to plati-
num and guiding patient treatment decisions.
Interestingly, our results also point to the upregulation
of a number of genes in the VCX/Y and PNMA families,
the functions of which are currently unknown. Further
studies will be required to assess whether these differen-
tially regulated genes play a crucial role in conferring
resistance to carboplatin.
Our gene expression data suggest a possible mechanism
for resistance to carboplatin in SCLC cells and begin to
reveal a distinct mode of action for picoplatin. Further
studies will be required to conﬁrm our ﬁndings in addi-
tional platinum-resistant SCLC cell lines and establish a
potential signature for platinum resistance. Since the
kinetics of DNA binding of picoplatin and cell cycle/death
response to picoplatin appear to be somewhat slow relative
to other platinums [5], gene expression proﬁling of plati-
num-treated tumor cells over time may prove to be useful.
Based on our ﬁnding that picoplatin treatment can over-
come resistance to other platinum drugs and the observa-
tion that picoplatin elicits a gene expression proﬁle that is
distinct from that of carboplatin in SCLC, we believe that
additional studies along this line of inquiry could help to
determine the mechanism of action for picoplatin and
potentially have clinical application by the establishment of
gene expression signature of carboplatin resistance in
SCLC.
The primary objective of this work was to determine
whether picoplatin could overcome resistance to treatment
by cisplatin and carboplatin in small-cell lung cancer. We
found that picoplatin retains cytotoxic activity against
cisplatin and carboplatin-resistant SCLC lines. In addition,
our results demonstrated that platinum-resistant cells
accumulated less platinum and differential gene expres-
sion. Picoplatin treatment resulted in high levels of plati-
num accumulation in all resistant and parental lines tested,
suggesting that mechanisms controlling cellular cisplatin
and carboplatin levels were not effective in controlling
cellular picoplatin levels. Finally, we showed by gene
expression proﬁling that picoplatin treatment triggers a
distinct gene expression pattern relative to treatment with
carboplatin and that this pattern is similar in parental and
carboplatin-resistant SCLC cell line. Together our data
suggest that picoplatin action is distinct from those of the
other platinums tested and could have clinical beneﬁt in the
treatment of small-cell lung cancer resistant to cisplatin and
carboplatin therapy.
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